Vendor Onboarding Timelines: The 90-Day Myth

The 90-day promise is a sales artefact

Walk into any vendor pitch and you'll hear a 90-day mobilisation timeline. It's repeated so often it's become shorthand for "we're fast." But the 90 days almost never refers to a fully operational trial with sites activated, monitoring in place, and first patient enrolled. It refers to the kickoff meeting, the project plan, and the first draft of the integrated quality risk management plan (IQRMP). Useful, but a long way from first patient in.

Once you peel back the layers, a realistic full-service CRO onboarding for a Phase 2 or 3 trial is 120 to 180 days from contract signature to first patient dosed. Functional service provider (FSP) models can be faster, but only because the scope is narrower. Anyone quoting 90 days to operational readiness for a multi-region, multi-therapeutic-area trial is either being optimistic or omitting steps.

Where the time actually goes

The realistic onboarding timeline has six distinct phases. None of them are optional:

• Contract and budget finalisation (2–4 weeks): Even with master service agreements in place, the protocol-specific statement of work and budget go through multiple rounds. Hidden in here are technology enablement costs, pass-through expenses, and per-patient budgets that often differ from the RFP response.
• System provisioning and access (2–3 weeks): CTMS, EDC, eTMF, IWRS, vendor portals. Each has its own access request, validation, and user acceptance test. The vendor's IT backlog is the silent killer here.
• Document collection and submission (3–6 weeks): CVs, training certificates, SOPs, financial disclosures, FDA Forms 1572, delegation logs. If the vendor's document repository isn't ready on day one, this phase stretches.
• Site identification and feasibility (4–8 weeks): Even if the sponsor has pre-identified sites, the vendor's feasibility process rarely accepts a sponsor's shortlist at face value. Expect re-feasibility on at least 30% of sites.
• Regulatory and ethics submissions (4–12 weeks): MHRA, REC, and country-specific submissions don't parallelise cleanly. The vendor's regulatory team's workload is the constraint.
• Site initiation visits and activation (3–6 weeks per site): SIV scheduling depends on the vendor's CRA availability. With industry-wide CRA turnover at 25–30%, expect gaps.

The compounding effect is why "90 days" rarely translates to anything operational. The first two or three sites might activate inside 90 days, but the bulk of the trial is months behind that.

The cost of underestimating onboarding

Industry data consistently shows that 40–50% of trials miss their first patient-in (FPI) target date. The most common reason isn't recruitment failure, it's onboarding slippage. The downstream cost is significant. Industry estimates put the average cost of a one-month trial delay at roughly $600,000 in extended site contracts, additional monitoring hours, and lost opportunity cost on the asset.

Sponsors who build their trial plan around the vendor's 90-day promise end up with compressed site activation, rushed monitoring, and pressure on the sites themselves. That's the recipe for protocol deviations, data quality issues, and ultimately, the kinds of findings that show up in regulatory inspections.

What realistic planning looks like

Three things change the game:

• Ask for the phase-by-phase timeline, not the headline number. "90 days to first site initiated" is a different statement from "90 days to first patient dosed." Get the vendor to break it down by deliverable and ownership line.
• Pressure-test the IT and document provisioning. Most onboarding delays trace back to access requests stuck in IT queues and documents missing from repositories. Ask the vendor for their last three activation timelines and where the slippage happened.
• Build contingency into the site activation plan. Plan for 120 days to first patient in as the base case, with 90 days as the upside. Anything tighter is a sales claim, not a plan.

How vendor evidence changes the conversation

Onboarding performance is one of the most opaque metrics in vendor selection. Most sponsors only learn a vendor's true onboarding speed by hiring them. By then, the cost of switching is too high.

Clinical Vendor Compare exists to surface these patterns before contract signature. The vendors who consistently deliver realistic onboarding timelines (and have the references to prove it) are the ones who tend to be the better long-term partners. The ones who promise 90 days and deliver 180 are the ones who also miss recruitment milestones, blow change orders, and burn through CRAs.

Vendor selection isn't about the optimistic number. It's about which vendors have evidence behind their timeline and which are just selling speed.